Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eflornithine/sulindac conjugate - Cellix Bio

Next Previous
Drug Profile

Eflornithine/sulindac conjugate - Cellix Bio

Alternative Names: CLX-157; CLX-ONC-57; CLX-ONC-575

Latest Information Update: 03 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellix Bio
  • Class Antineoplastics; Basic amino acids; Diamino amino acids; Drug conjugates; Indenes; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Ornithine decarboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Familial adenomatous polyposis

Most Recent Events

  • 22 Sep 2022 Eflornithine/sulindac conjugate is still in preclinical phase for Familial Adenomatous Polyposis (FAP) in India (Cellix Bio pipeline, September 2022).
  • 28 Jul 2022 No recent reports of development identified for preclinical development in Familial-adenomatous-polyposis in India
  • 16 Jul 2020 Preclinical development is still ongoing in India (Cellix Bio pipeline, July 2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top